Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. (September 2019)

• Record Type: Journal Article
• Authors: Fleischmann, Daniel Felix; Jenn, Johanna; Corradini, Stefanie; Ruf, Viktoria; Herms, Jochen; Forbrig, Robert; Unterrainer, Marcus; Thon, Niklas; Kreth, Friedrich Wilhelm; Belka, Claus; Niyazi, Maximilian
• Is Part Of: Radiotherapy and oncology. Volume 138(2019)
• Page Start: 99
• Page End: 105
• Publication Date: 2019-09
• Subjects: Bevacizumab -- Recurrent glioma -- Reirradiation -- Glioblastoma; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2019.06.009
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Toxicity of reRT plus BEV was compared to reRT only for recurrent glioma patients. Radionecrosis and symptomatic oedema (RN/SE) were less frequent in reRT plus BEV. RN/SE rate was 21.8% (27/124) for reRT plus BEV and 37.8% (14/37) for reRT only. No BEV was the only significant risk factor for RN/SE on multivariate analysis. Abstract: Purpose: The role of bevacizumab (BEV) in the setting of reirradiation (reRT) of malignant glioma recurrences is poorly defined. At our institution, reRT plus BEV was routinely used until its disapproval for glioma treatment by the European Medical Agency. Accordingly, reRT was applied without the addition of BEV since 2017. Here we present for the first time outcome and toxicity profiles of reRT plus BEV and reRT alone for malignant glioma recurrences. Patients and methods: All adult patients consecutively undergoing reRT of a recurrent malignant glioma (37 anaplastic astrocytoma, WHO III; 124 glioblastoma, WHO IV) between 2007 and 2017 were included. In one group of patients, BEV (10 mg/kg bodyweight) was applied concomitantly on days 1 and 15 of reRT. Radiation toxicity referred to clinically significant toxicities of proven symptomatic radionecrosis (RN) and symptomatic oedema (SE) requiring steroid treatment for more than six weeks after reRT. Post-recurrence survival (PRS) and freedom from RN/SE were estimated with the Kaplan–Meier method. Prognostic factors were obtained from proportional hazards models. Results: BEV plus reRT was applied in 124 and reRT alone in 37 patients. Both groups were comparable in terms of their patient-, tumour-, and RT/reRT-related variables. PRS was independent from the applied reRT protocols. RN/SE was less frequently seen after reRT plus BEV absolutely (27/124 (21.8%) vs. 14/37 (37.8%) patients; p = 0.025) and over time (1-year RN/SE rate: 23.9% vs. 54.1%; p = 0.013). The unadjusted and adjusted hazard ratio for RN/SE was doubled in case of reRT alone. Absence of BEV remained the only risk factor for RN/SE in multivariate models ( p = 0.026). Conclusion: Concomitant BEV effectively reduces treatment toxicity of reRT and should be reconsidered in future reRT protocols.